Friday, November 13, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Shell plc publishes fourth quarter 2025 press release

View original at finance.yahoo.com
“Free cash flow 8.7 5.3 6.5 10.0 4.2 (table row, columns Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025; units $ billion)”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If society is not net zero in 2050, there would be significant risk that Shell may not meet its 2050 net-zero emissions target

    80% confidence

  • Shell delivered $2.0 billion in structural cost reductions in 2025

    80% confidence

  • Shareholder distributions represented approximately 52% of cash flow from operations in 2025

    80% confidence

  • Q4 cash delivery remained solid despite lower earnings in a softer macro environment

    80% confidence

  • 2025 was a year of accelerated momentum, with strong operational and financial performance across Shell

    80% confidence

  • As society moves towards net-zero emissions, Shell expects its operating plans and outlooks to reflect this movement

    80% confidence

  • Shell reached $5 billion of cost savings since 2022, with more to come

    80% confidence

  • Shell generated free cash flow of $26 billion in 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com
Shell plc publishes fourth quarter 2025 press release — Source | Via News | Finance Via News